Home / Leaderboard / OrbiMed Advisors LLC
OrbiMed Advisors LLC
Sven H. Borho · Investment Advisor · Multi-Strategy
OrbiMed Advisors LLC is a premier global investment firm exclusively dedicated to the healthcare and biotechnology sectors. Established in 1989, the firm manages a broad range of investment vehicles, including venture capital, private equity, and public equity funds, as well as royalty and credit monetization solutions. OrbiMed invests across the entire life cycle of companies, from seed-stage start-ups to large multinational corporations, aiming to drive medical innovation and address significant unmet clinical needs. With approximately $18 billion in assets under management and a team of more than 150 professionals, the firm operates globally from its New York headquarters and offices in San Francisco, London, Shanghai, Hong Kong, Mumbai, and Herzliya. OrbiMed is widely regarded as one of the world's largest and most influential healthcare-focused investment managers, leveraging its deep scientific and medical expertise to identify transformative opportunities in the global health sciences market.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +68.6% |
| YTD return | +12.9% |
| Sharpe ratio | 4.38 |
| Win rate | 55% |
| AUM | $3.4B |
| Inception | Oct 1, 2025 |
| Updated | Aug 20, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $3.4B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://www.orbimed.com |
Current Holdings
Updated on Aug 20, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| EWTX | Edgewise Therapeutics Inc | 19.5% | +76.3% |
| ELVN | Enliven Therapeutics Inc. | 11.4% | +91.4% |
| BRVE | Braveheart Bio, Inc. Common Stock | 9.0% | +1.4% |
| LLY | Eli Lilly and Company | 8.2% | +37.8% |
| ARGX | argenx NV ADR | 6.8% | +30.2% |
| MBX | MBX Biosciences, Inc. Common Stock | 6.1% | +139.9% |
| BSX | Boston Scientific Corp | 3.6% | -38.8% |
| EW | Edwards Lifesciences Corp | 3.3% | +12.8% |
| CRVS | Corvus Pharmaceuticals Inc | 3.1% | -34.5% |
| PRLD | Prelude Therapeutics Inc | 3.1% | +40.5% |
| AZN | AstraZeneca PLC | 3.0% | -6.6% |
| QURE | Uniqure NV | 2.9% | +66.7% |
| FBRX | Forte Biosciences Inc | 2.7% | +0.4% |
| AVBP | ArriVent BioPharma, Inc. Common Stock | 2.6% | +12.0% |
| MRK | Merck & Company Inc | 2.6% | +21.9% |
| CRNX | Crinetics Pharmaceuticals Inc | 2.5% | +1.3% |
| IRON | Disc Medicine Inc. | 2.4% | +17.4% |
| ISRG | Intuitive Surgical Inc | 2.4% | -15.6% |
| NTRA | Natera Inc | 2.4% | +0.9% |
| GPCR | Structure Therapeutics Inc. American Depositary Shares | 2.3% | -4.9% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Aug 17, 2026 | BUY | LLY | 8.6% → 8.2% |
| Aug 17, 2026 | SELL | ARGX | 7.4% → 6.8% |
| Aug 17, 2026 | SELL | QURE | 3.0% → 2.9% |
| Aug 17, 2026 | SELL | ELVN | 12.6% → 11.4% |
| Aug 17, 2026 | SELL | MRK | 2.6% → 2.6% |
Investment Style Analysis
OrbiMed Advisors LLC is widely recognized for employing a Multi-Strategy strategy. As of Aug 20, 2026, the firm oversees approximately $3.4B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology and Drug Manufacturers - General sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Aug 17, OrbiMed Advisors LLC made a significant move by increasing exposure to LLY. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
OrbiMed’s investment philosophy is rooted in the belief that the healthcare industry offers unique and powerful growth opportunities driven by global demographics and scientific innovation. The firm employs a fundamental, research-driven approach, combining deep medical and scientific knowledge with financial expertise to support companies at all stages of development. By investing across the capital structure—including early-stage venture capital, growth equity, and public markets—OrbiMed aims to provide tailored financing solutions that help build market-leading companies. Their strategy focuses on identifying breakthrough technologies in areas like biopharmaceuticals and medical devices that can significantly improve patient outcomes and create long-term shareholder value.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with OrbiMed Advisors LLC.
Similar Investment Style
Based on Multi-Strategy.
- Sandoz Family Office SA — Marc Duc · 3M +2.3%
- BB Gestão de Recursos - Distribuidora de Títulos e Valores Mobiliários S.A. — Denísio Liberato · 3M -5.0%
- Wolverine Trading, LLC — Robert Bellick · 3M -0.3%
- Amundi Asset Management US, Inc. — Marco Pirondini · 3M -1.8%
Frequently asked questions
How is the simulated portfolio for OrbiMed Advisors LLC constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is OrbiMed Advisors LLC's largest holding?
As of the latest filing, OrbiMed Advisors LLC's top position is Edgewise Therapeutics Inc (EWTX), representing 19.5% of the portfolio. This reflects a high-conviction bet by the institution.
What is OrbiMed Advisors LLC's historical performance and risk profile?
Our simulation indicates a total return of +68.6% with a win rate of 55%. Notably, the portfolio maintains a Sharpe Ratio of 4.38, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does OrbiMed Advisors LLC primarily invest in?
OrbiMed Advisors LLC has a strong preference for the Biotechnology sector, which makes up 74.4% of their disclosed assets. The portfolio also has exposure to Drug Manufacturers - General, indicating a specific thematic focus.
Is OrbiMed Advisors LLC's portfolio concentrated or diversified?
OrbiMed Advisors LLC runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 40.0% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has OrbiMed Advisors LLC performed in 2026?
Our AI-simulated model portfolio for OrbiMed Advisors LLC tracks a Year-to-Date (YTD) return of +12.9%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Sven H. Borho manage OrbiMed Advisors LLC directly?
Yes, Sven H. Borho serves as the key portfolio manager for OrbiMed Advisors LLC, overseeing the investment strategy and final capital allocation decisions.